TRUSTEES OF BOSTON UNIVERSITY;HEMAQUEST PHARMACEUTICALS, INC.
发明人:
申请号：
IL22004012
公开号：
IL220040D0
申请日:
2012.05.29
申请国别(地区):
IL
年份:
2012
代理人:
摘要：
Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks.
